Watch List: CARDIFF INTL, Cord Blood America, Net Savings Link, Titan Pharmaceuticals

Lakeway, TX -- (SBWIRE) -- 03/20/2013 -- Bestdamnpennystocks, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

CARDIFF INTL INC (OTC: CDIF) surged up 32.65% to $0.0065 on a traded volume of 9.39 million shares. So far this year, the stock is down over 22%. The 52-week range for the stock is $0.0 and $0.12. Cardiff International, Inc., a development stage company, doing business as Legacy Card Company, engages in developing a proprietary software system to track and manage consumer purchases.

How Should Investors Trade CDIF After The Recent Movement? Find Out Here

Cord Blood America Inc. (OTC: CBAI) went up 8.82% to $0.0037 on a traded volume of 4.18 million shares. So far this year, the stock is down over 20%. The 52-week range for the stock is $0.0 and $0.03. Cord Blood America, Inc. is a holding company. CBAI is primarily an umbilical cord blood stem cell preservation company, with a particular focus on the acquisition of customers in need of family based products and services.

Is CBAI Strong Buy After The Recent Strong Gains? Get Free Trend Analysis Here

Net Savings Link Inc. (PINK: NSAV) went down 25.0% to $0.0003 on a traded volume of 25.97 million shares. The 52-week range for the stock is $0.0 and $0.09. The Company has Price/Sales ratio of 1.37. The 50-Day Moving Average and 200-Day Moving Average prices is $0.0 and $0.01 respectively. Net Savings Link, Inc. is an online provider of discount offers and savings opportunities to the mass consumer market. The Company delivers discount offers and savings opportunities to the mass consumer market through an electronic membership participation program.

Is NSAV a Buying Opportunity After The Recent Plunge? Don’t Miss Out Our Latest Report Here

Titan Pharmaceuticals, Inc. (OTC: TTNP) augmented 18.49% to $1.41 on a traded volume of 1.90 million shares. The U.S. Food and Drug Administration said in documents published, Titan Pharmaceuticals Inc.'s experimental drug to treat opioid addiction was shown to be more effective than placebo in a clinical trial, but the results were not as strong as might be hoped. The reviewers' commentary was published on the FDA's website ahead of an advisory panel meeting. The reviewers said results of the trial prompt speculation that Titan's drug needs to be given at a higher dose and they asked the panel to advise on whether the company should explore dosing further before the product is approved.

How Should Investors Trade TTNP After The Latest Earnings Report? Find Out Here

About bestdamnpennystocks.com

Best Damn Penny Stocks’ team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer
The assembled information disseminated by Bestdamnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Bestdamnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in Bestdamnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.